COPENHAGEN, Denmark and REDWOOD CITY, California, February 21 /PRNewswire/ --
- Summary: Genmab and PDL BioPharma Have Entered into an Agreement Under Which Genmab Will Acquire PDL's Antibody Manufacturing Facility Located in Brooklyn Park, Minnesota, USA.
Genmab A/S (OMX: GEN) and PDL BioPharma, Inc. (Nasdaq: PDLI) announced today that they have entered into an agreement under which Genmab would acquire PDL's antibody manufacturing facility located in Brooklyn Park, Minnesota, USA for USD 240 million to be paid in cash. The transaction also includes land, equipment and access to a leased space housing a development lab.